Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

Key Takeaways

• FDA‑approved topical keratoconus therapy, no epithelium removal.
• Reduces procedure pain and shortens recovery time.
• Available now through Glaukos and specialty distributors.
• Includes co‑pay and uninsured patient assistance programs.
• Supports broader screening and early diagnosis initiatives.

Summary

Glaukos announced that Epioxa™ HD/Epioxa™ is now commercially available, marking the first FDA‑approved, incision‑free topical drug for keratoconus. The therapy uses a riboflavin solution with the O₂n™ System and Boost Goggles, eliminating the need to remove the corneal epithelium. By reducing pain and shortening recovery, Epioxa offers a less invasive alternative to traditional cross‑linking. Glaukos is also launching patient‑access programs, co‑pay assistance, and awareness campaigns to broaden adoption.

Pulse Analysis

Keratoconus, a progressive thinning of the cornea, has traditionally been managed with epithelium‑off corneal collagen cross‑linking (CXL), a procedure that requires surgical removal of the surface layer, causing discomfort and a week‑long healing period. Glaukos’ Epioxa™ HD/Epioxa™ introduces an FDA‑approved, incision‑free, riboflavin‑based topical solution that works in conjunction with the O₂n™ System and Boost Goggles to deliver oxygen‑enhanced cross‑linking while the epithelium remains intact. Clinical data show comparable biomechanical strengthening with significantly lower rates of postoperative pain and faster visual recovery, positioning the therapy as a true paradigm shift in corneal care.

The launch expands Glaukos’ corneal portfolio beyond its existing CXL product, targeting a niche yet underserved market of roughly 1‑2 % of the global population. By bundling co‑pay assistance, uninsured patient programs, and a dedicated access‑liaison team, the company aims to overcome the historic barriers of underdiagnosis and cost that have limited adoption. Analysts anticipate that the convenience of a topical regimen will drive higher procedure volumes, especially in outpatient ophthalmology practices, and may attract insurance coverage that previously balked at the procedural complexity of traditional CXL. This could translate into multi‑digit revenue growth for Glaukos in the next few years.

Epioxa’s approval reflects a broader industry move toward droplet‑free, minimally invasive ocular therapies, echoing trends seen in glaucoma micro‑invasive surgery and long‑acting intra‑ocular drug depots. The regulatory milestone underscores the FDA’s willingness to endorse novel delivery platforms that improve patient experience without compromising efficacy. As ophthalmologists increasingly seek solutions that reduce clinic time and enhance compliance, other biotech firms are likely to accelerate development of similar epithelium‑on cross‑linking agents or photochemical treatments. For investors, Glaukos’ early entry offers a competitive moat, while patients benefit from a safer, more comfortable pathway to halt keratoconus progression.